Quicksilver Scientific

Due to inclement weather and increased order volume expect shipping delays. 

Free shipping over $50


Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

PushCatch® Liver Detox References

  1. Grand D.M. Detoxification pathways in the liver. J Inherit Metab Dis. 1991; 14(4): 421-430.
  2. Leslie EM, et al. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005; 204(3): 216-237.
  3. Zamek-Gliszczynski MJ, et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and GSH metabolites. Eur J Pharm Sci. 2006; 27(5): 447-486.
  4. Trauner M, et al. Bile salt transporters: Molecular characterization, function, and regulation. Physiol Rev. 2003; 83(2): 633-671.
  5. Nguyen T, et al. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009; 284(20): 13291-13295.
  6. Ganey PE, et al. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology. 2001; 169(3): 195-208.
  7. Urdaneta V and Casadesus J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front Med (Lausanne). 2017; 4: 163.
  8. Islam KB, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterol. 2011; 141(5): 1773-1781.
  9. Inagaki T, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA. 2006; 103(10): 3920-3925.
  10. Sadiq FA, et al. Lactic acid bacteria as antifungal and anti‐mycotoxigenic agents: A comprehensive review. Comp Rev Food Sci Food Saf. 2019; 18(5): 1403-1436.
  11. Kinoshita H. Biosorption of heavy metals by lactic acid bacteria for detoxification. Methods Mol Biol. 2019; 1887: 145-157.
  12. Li C, et al. Screening for Lactobacillus plantarum strains that possess organophosphorus pesticide-degrading activity and metabolomic analysis of phorate degradation. Front Microbiol. 2018; 9: 2048.
  13. Kalitsky-Szirtes J, et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004; 32(1): 20-27.
  14. Awad WA, et al. Enteric pathogens and their toxin-induced disruption of the intestinal barrier through alteration of tight junctions in chickens. Toxins (Basel). 2017; 9(2).
  15. Yu Y, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol. 2015; 97(2): 173-177.
  16. Shaik F.A., et al. Bitter taste receptors: Extraoral roles in pathophysiology. Int J Biochem Cell Biol. 2016; 77(Pt B): 197-204.
  17. Lee RJ and Cohen NA. The emerging role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis. Am J Rhinol Allergy. 2013; 27(4): 283-286.
  18. Gaida MM, et al. Sensing developing biofilms: The bitter receptor T2R38 on myeloid cells. Pathog Dis. 2016; 74(3).
  19. Tang X, et al. Target profiling analyses of bile acids in the evaluation of hepatoprotective effect of gentiopicroside on ANIT-induced cholestatic liver injury in mice. J Ethnopharmacol. 2016; 194(24): 63-71.
  20. Mirzaee F, et al. Medicinal, biological and phytochemical properties of Gentiana species. J Tradit Complement Med. 2017; 7(4): 400-408.
  21. Gonzalez-Castejon M, et al. Diverse biological activities of dandelion. Nutr Rev. 70(9): 534-547.
  22. Liu B, et al. Taraxasterol inhibits LPS-induced inflammatory response in BV2 microglia cells by activating LXRα. Front Pharmacol. 2018; 9: 278.
  23. Esatbeyoglu T, et al. Sesquiterpene lactone composition and cellular Nrf2 induction of Taraxacum officinale leaves and roots and Taraxinic Acid β-d-Glucopyranosyl Ester. J Med Food. 2017; 20(1): 71-78.
  24. Chodera A, et al. Effect of flavonoid fractions of Solidago virgaurea L on diuresis and levels of electrolytes. Acta Pol Pharm. 1991; 48(5-6): 35-37.
  25. Apati P, et al. In-vitro effect of flavonoids from Solidago canadensis extract on glutathione S-transferase. J Pharm Pharmacol. 2006; 58(2): 251-256.
  26. Deng R, et al. The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over farnesoid X receptor-mediated antagonism. J Pharmacol Exp Ther. 2007; 320(3): 1153-1162.
  27. Sarup P, et al. Pharmacology and phytochemistry of oleo-gum resin of Commiphora wightii (Guggulu). Scientifica (Cairo). 2015; 2015: 138039.
  28. Crocenzi FA, et al. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem. 2006; 13(9): 1055-1074.
  29. Abenavoli L, et al. Milk thistle in liver diseases: Past, present, future. Phytother Res. 2010; 24(10): 1423-1432.
  30. Gu M, et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol. 2016; 7: 345.
  31. Crocenzi FA, et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: A study in vivo and in isolated hepatocyte couplets. Hepatology. 2001; 34(2): 329-339.
  32. Suh JH, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA. 2004; 101(10): 3381-3386.
  33. Arredondo F, et al. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against oxidative insult. Free Radic Biol Med. 2010; 49(5): 738-747.
  34. Saw CL, et al. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug-metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos. 2011; 32(5): 289-300.
  35. Micek J, et al. Quercetin and its anti-allergic immune response. Molecules. 2016; 21(5).
  36. Seelinger G, et al. Anti-oxidant, anti-inflammatory, and anti-allergic activities of luteolin. Planta Med. 2008; 74(14): 1667-1677.
  37. Suzuki T and Hara H. Quercetin enhances intestinal barrier function through the assembly of zonula occludens-2, occludin, and claudin-1 and the expression of claudin-4 in caco-2 cells. J Nutr. 2009; 139(5): 965-974.
  38. Mohammedelnour AA, et al. Effect of solvent types on phenolics content and antioxidant activities of Acacia polyacantha gum. Int Food Res J. 2017; 24: Suppl S369-S377.
  39. Liu G, et al. Chitosan modulates inflammatory responses in rats infected with enterotoxigenic Escherichia coli. Med Inflamm. 2016; 7432845.
  40. Vaziri ND, et al. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol. 2013; 37: 518-525.
  41. Sanchez A, et al. Influence of preparation methods of chitooligosaccharides on their physiochemical properties and their anti-inflammatory effects in mice and in RAW 264.7 macrophages. Mar Drugs. 2018; 16(11).
  42. Langmead L, et al. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004; 19(5): 521-527.
  43. Im SA, et al. In vivo evidence of the immunomodulatory activity of orally administered Aloe vera gel. Arch Pharm Res. 2010; 33(3): 451-456.
  44. Cherbut C, et al. Acacia gum is a Bifidogenic dietary fibre with high digestive tolerance in healthy humans. Microb Ecol Health Dis. 2003; 15(1): 43-50.
  45. Suthongsa S, et al. Effects of dietary levels of chito-oligosaccharide on ileal digestibility of nutrients, small intestinal morphology, and crypt cell proliferation in weaned pigs. Livest Sci. 2017; 198: 37-44.
  46. Neuvonen PJ and Olkkola KT. Oral activated charcoal in the treatment of intoxications: Role of single and repeated doses. Med Toxicol. 1988; 3: 33-58.
  47. Bhatti SA, et al. Protective role of bentonite against aflatoxin B1- and ochratoxin A-induced immunotoxicity in broilers. J Immunotoxicol. 2017; 14(1): 66-76.
  48. Li X, et al. Carbohydrate functionalized chitosan fiber for influenza virus capture. Biomacromolecules. 2011; 12: 3962-3969.
  49. Guan G, et al. Biological effects and applications of chitosan and chito-oligosaccharides. Front Physiol. 2019; 10.3389/fphys.2019.00516.
  50. Vighi G, et al. Allergy and the gastrointestinal system. Clin Exp Immunol. 2008; 153(Suppl 1): 3-6.
  51. Fukui H. Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation? Inflamm Intest Dis. 2016; 1(3): 135-145.
  52. Salguero MV, et al. Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med. 2019; 18(5): 3461-3469.
  53. Aguiniga LM, et al. Lipopolysaccharide domains modulate urovirulence. Infect Immun. 2016; 84(11): 3131-3140.
  54. Ebersole JL, et al. Systemic endotoxin levels in chronic indolent periodontal infections. J Periodontal Res. 2010; 45(1): 1-7.
  55. Hartmann G, et al. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002; 303(1): 273-281.
  56. Bolder U, et al. Hepatocyte transport of bile acids and organic anions in endotoxemic rats. Impaired uptake and secretion. Gastroenterology. 1997; 112: 214-225.
  57. Cherrington NJ, et al. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos. 2004; 32(7): 734-741.
  58. Tang W, et al. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol Cell Biol Res Commun. 2000; 4(2): 90-97.
  59. Ditter B, et al. Ability of various adsorbents to bind endotoxins in vitro and to prevent orally induced endotoxemia in mice. Gastroenterology. 1983; 84(6): 1547-1552.
  60. Khalid J, et al. Medical and environmental applications of activated charcoal: Review article. Eur Sci J. 2015; 11(3): 50-56.
  61. Karnib M, et al. Heavy metals removal using activated carbon, silica and silica activated carbon composite. Energy Procedia. 2014; 50: 113-120.
  62. Du XN, et al. Effect of activated charcoal on endotoxin adsorption. Part I. An in vitro study. Biomater Artif Cells Artif Organs. 1987; 15(1): 229-235.
  63. Zellner T, et al. The use of activated charcoal to treat intoxications. Dtsch Arztebl Int. 2019; 116(18): 311-317.
  64. Krasopoulos JC, et al. The adsorption of bile salts on activated carbon. Lipids. 1980; 15(5): 365-370.
  65. Musso CG et al. Combination of oral activated charcoal plus low protein diet as a new alternative for handling in the old end-stage renal disease patients. Saudi J Kidney Dis Transpl. 2010; 21(1): 102-104.
  66. Koide SS. Chitin-chitosan: Properties, benefits, and risks. Nutrition Research. 1998; 8(6): 1091-1101.
  67. Lutjohann D, et al. Influence of chitosan treatment on surrogate serum markers of cholesterol metabolism in obese subjects. 2018; 10(1): 72.
  68. Trivedi VR, et al. Single-blind, placebo-controlled randomized clinical study of chitosan for body weight reduction. Nutr J. 2015; 15(3).
  69. Xiao D, et al. Effects of dietary administering chitosan on growth performance, jejunal morphology, jejunal mucosal sIgA, occludin, claudin-1 and TLR4 Expression in weaned piglets challenged by enterotoxigenic Escherichia coli. Int Immunopharmacol. 2013; 17(3): 670-676.
  70. Chkuaseli A, et al. Application of new mycotoxin adsorbent-bentonite clay “Askangel” in poultry feed. Ann Agr Sci. 2016; 14(4): 295-298.
  71. Haydel SE, et al. Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens. J Antimicrob Chemother. 2008; 61(2): 353-361.
  72. Schaumberger S, et al. Evaluation of the endotoxin binding efficiency of clay minerals using the Limulus Amebocyte lysate test: An in vitro study. B. Express. 2014; 4: 1.
  73. Zhao W, et al. Thiol-functionalized mesoporous silica for effective trap of mercury in rats. J Nanomater. 2016; Article ID: 9758264.
  74. Pressman P, et al. Aloe vera at the frontier of glycobiology and integrative medicine: Health implications of an ancient plant. Sage Open Med. 2019; 7.
  75. Quezada MP, et al. Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics. J Agric Food Chem. 2017; 65(46): 10029-10039.
  76. Hekmatpou D, et al. The effect of Aloe vera clinical trials on prevention and healing of skin wound: A systematic review. Iran J Med Sci. 2019; 44(1): 1-9.
  77. Hes M, et al. Aloe vera (L.) Webb.: Natural sources of antioxidants – A review. Plant Foods Hum Nutr. 2019; 74(3): 255-265.
  78. Calame W, et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. Br J Nutr. 2008; 100(6): 1269-1275.
  79. Babiker R, et al. Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial. Lipids Health Dis. 2018; 17: 56.
  80. Daguet D, et al. Acacia gum improves the gut barrier functionality in vitro. Agro Food Industry Hi Tech. 2015; 26(4): 29-33.
  81. Daguet D, et al. Arabinogalactan and fructooligosaccharides improve the gut barrier function in distinct areas of the colon in the Simulator of the Human Intestinal Microbial Ecosystem. J Fuct Foods. 2016; 20: 369-379.
  82. Spector AA and Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985; 26(9): 1015-1035.
  83. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997; 14(4): 333-393.
  84. Ahn H and Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016; 20: 36.
  85. Alyautdin R, et al. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014; 9: 795-811.
Your Cart